Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4088/jcp.v64n0618a | DOI Listing |
Pharmaceuticals (Basel)
October 2024
Clinical Analysis Laboratory, Molecular Pathology Sector, Pharmacy Department, Faculty of Ceilândia, University of Brasília (UnB), Brasília-Federal District (DF), Brasília 72220-900, Brazil.
Pharmacogenomics J
November 2024
Campbell Family Mental Health Research Institute, Center for Addiction and Mental Health, Toronto, ON, Canada.
Late-life depression (LLD) is often accompanied by medical comorbidities such as psychiatric disorders and cardiovascular diseases, posing challenges to antidepressant treatment. Recent studies highlighted significant associations between treatment-resistant depression (TRD) and polygenic risk score (PRS) for attention deficit hyperactivity disorder (ADHD) in adults as well as a negative association between antidepressant symptom improvement with both schizophrenia and bipolar. Here, we sought to validate these findings with symptom remission in LLD.
View Article and Find Full Text PDFPharmacol Res
October 2024
Department of Pediatrics, PICU, Shengjing Hospital of China Medical University, Shenyang 110004, China. Electronic address:
Mol Genet Metab
August 2024
Mater Research Institute-University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia. Electronic address:
Glutaric aciduria type II (GAII) is a heterogeneous genetic disorder affecting mitochondrial fatty acid, amino acid and choline oxidation. Clinical manifestations vary across the lifespan and onset may occur at any time from the early neonatal period to advanced adulthood. Historically, some patients, in particular those with late onset disease, have experienced significant benefit from riboflavin supplementation.
View Article and Find Full Text PDFPsychiatry Clin Neurosci
August 2024
Service Hospitalo-Universitaire de Psychiatrie, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
Background: Habenula, a hub brain region controlling monoaminergic brain center, has been implicated in major depressive disorder (MDD) and as a possible target of antidepressant response. Nevertheless, the effect of antidepressant drug treatment on habenular volumes remains unknown. The objective of the present research was to study habenular volume change after antidepressant treatment in patients with MDD, and assess whether it is associated with clinical improvement.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!